These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 31823044)
21. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe]. Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391 [TBL] [Abstract][Full Text] [Related]
22. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995 [TBL] [Abstract][Full Text] [Related]
23. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. Ennis JL; Worcester EM; Coe FL; Sprague SM J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620 [TBL] [Abstract][Full Text] [Related]
24. [Renal osteodystrophy (3); its treatment in dialysis patients]. Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385 [TBL] [Abstract][Full Text] [Related]
25. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755 [TBL] [Abstract][Full Text] [Related]
26. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)]. Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221 [TBL] [Abstract][Full Text] [Related]
27. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817 [TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978 [TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604 [TBL] [Abstract][Full Text] [Related]
30. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management. Pazianas M; Miller PD J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482 [TBL] [Abstract][Full Text] [Related]
31. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD]. Koiwa F; Maruta Y Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188 [TBL] [Abstract][Full Text] [Related]
32. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571 [TBL] [Abstract][Full Text] [Related]
33. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. McAlister L; Pugh P; Greenbaum L; Haffner D; Rees L; Anderson C; Desloovere A; Nelms C; Oosterveld M; Paglialonga F; Polderman N; Qizalbash L; Renken-Terhaerdt J; Tuokkola J; Warady B; Walle JV; Shaw V; Shroff R Pediatr Nephrol; 2020 Mar; 35(3):501-518. PubMed ID: 31667620 [TBL] [Abstract][Full Text] [Related]
34. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Komaba H; Tanaka M; Fukagawa M Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108 [TBL] [Abstract][Full Text] [Related]
35. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. Bellorin-Font E; Vasquez-Rios G; Martin KJ Curr Osteoporos Rep; 2019 Oct; 17(5):333-342. PubMed ID: 31485996 [TBL] [Abstract][Full Text] [Related]
36. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540 [TBL] [Abstract][Full Text] [Related]
37. Managing bone mineral disorders in CKD: an overview of current therapies. Delaney M J Ren Care; 2009 Mar; 35 Suppl 1():107-10. PubMed ID: 19222741 [No Abstract] [Full Text] [Related]
38. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739 [TBL] [Abstract][Full Text] [Related]
39. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]. Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181 [TBL] [Abstract][Full Text] [Related]
40. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]